Loading stock data…
Incyte Corporation (INCY)
$117.67+0.98 (+0.84%)
Market ClosedLast close Jul 24
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Incyte Corporation in the Healthcare sector is trading at $117.67 with a market capitalization of $19.3B. Wall Street consensus targets $114.55 (22 analysts), implying a -2.7% move over the next 12 months. The stock is currently near its 52-week high of $119.60, remaining 17.3% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.27B↓ | $1.51B↑ | $1.37B↑ | $1.22B↑ | $1.05B |
| Gross Profit | $1.17B↓ | $1.39B↑ | $1.27B↑ | $1.14B↑ | $979.70M |
| Operating Income | $324.17M↓ | $383.96M↓ | $431.30M↑ | $310.81M↑ | $216.72M |
| Net Income | $303.33M↑ | $299.28M↓ | $424.17M↑ | $405.00M↑ | $158.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycyth...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.33B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.66
Beta
Defensive asset. Lower volatility than the S&P 500.
0.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
25.46%
Volume
Today's trading volume
1.18M
Recent News
Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics
Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease. The company announced the acquisition of VGA039 (latarcibart) through the purchase of Vega Therapeutics to support further development. Latarcibart carries breakthrough, fast track, orphan drug, and rare pediatric disease designations. For investors tracking Incyte, this update sits at the intersection of rare disease drug...
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HALO Inks Deal With INCY to Support Cancer Therapy Development
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.